Quoin Pharmaceuticals, Ltd. (QNRX)
NASDAQ: QNRX · Real-Time Price · USD
4.210
-0.030 (-0.71%)
Jul 20, 2026, 4:00 PM EDT - Market closed
Quoin Pharmaceuticals Employees
As of December 31, 2025, Quoin Pharmaceuticals had 6 total employees, including 4 full-time and 2 part-time employees. The number of employees increased by 1 or 20.00% compared to the previous year.
Employees
6
Change (1Y)
1
Growth (1Y)
20.00%
Revenue / Employee
n/a
Profits / Employee
-$2,831,702
Market Cap
8.46M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 6 | 1 | 20.00% | 4 | 2 |
| Dec 31, 2024 | 5 | 1 | 25.00% | 3 | 2 |
| Dec 31, 2023 | 4 | 0 | - | 4 | 0 |
| Dec 31, 2022 | 4 | 0 | - | 4 | 0 |
| Dec 31, 2021 | 4 | 2 | 100.00% | 4 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Curis | 24 |
| Bolt Biotherapeutics | 23 |
| Imunon | 20 |
| BioRestorative Therapies | 14 |
| TransCode Therapeutics | 12 |
| Aprea Therapeutics | 8 |
| MetaVia | 8 |
| CNS Pharmaceuticals | 8 |
QNRX News
- 4 days ago - Quoin Pharmaceuticals Proxy statement: Proxy filing - Filings
- 11 days ago - Quoin Pharmaceuticals announces FDA clearance of QRX003 IND application - TheFly
- 11 days ago - Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome - GlobeNewsWire
- 14 days ago - Quoin Pharmaceuticals Proxy statement: Proxy filing - Filings
- 20 days ago - Quoin Pharmaceuticals receives notice of allowance for QRX003 patent - TheFly
- 20 days ago - Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome - GlobeNewsWire
- 27 days ago - Quoin Pharmaceuticals announces conditional FDA approval for Qyleki brand name - TheFly
- 27 days ago - Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome - GlobeNewsWire